Literature DB >> 30859301

Discrimination between recent and non-recent HIV infections using routine diagnostic serological assays.

Jaythoon Hassan1, Joanne Moran2,3, Gary Murphy4, Olivia Mason5, Jeff Connell2, Cillian De Gascun2.   

Abstract

The suitability of routine diagnostic HIV assays to accurately discriminate between recent and non-recent HIV infections has not been fully investigated. The aim of this study was to compare an established HIV recency assay, the Sedia limiting antigen HIV avidity assay (LAg), with the diagnostic assays; Abbott ARCHITECT HIV Ag/Ab Combo and INNO-LIA HIV line assays. Samples from all new HIV diagnoses in Ireland from January to December 2016 (n = 455) were tested. An extended logistic regression model, the Spiegelhalter-Knill-Jones method, was utilised to establish a scoring system to predict recency of HIV infection. As proof of concept, 50 well-characterised samples were obtained from the CEPHIA repository whose stage of infection was blinded to the authors, which were tested and analysed. The proportion of samples that were determined as recent was 18.1% for LAg, 6.4% with the ARCHITECT, and 14.5% in the INNO-LIA assay. There was a significant correlation between the ARCHITECT S/CO values and the LAg results, r = 0.717, p < 0.001. ROC analysis revealed that an ARCHITECT S/CO < 250 had a sensitivity and specificity of 90.32% and 89.83%, respectively. Combining the Abbott ARCHITECT HIV Ag/Ab Combo assay and INNO-LIA HIV assays resulted in an observed risk of being recent of 100%. Analysis of the CEPHIA samples revealed a strong agreement between the LAg assay and the combination of routine assays (κ = 0.908, p < 0.001). Our findings provide evidence that assays routinely employed to diagnose and confirm HIV infection may be utilised to determine the recency of HIV infection.

Entities:  

Keywords:  HIV infection; Recency; Routine diagnostic assays

Mesh:

Substances:

Year:  2019        PMID: 30859301     DOI: 10.1007/s00430-019-00590-0

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  19 in total

1.  Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection.

Authors:  A Manns; W J Miley; R J Wilks; O S Morgan; B Hanchard; G Wharfe; B Cranston; E Maloney; S L Welles; W A Blattner; D Waters
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

2.  Three methods to construct predictive models using logistic regression and likelihood ratios to facilitate adjustment for pretest probability give similar results.

Authors:  Siew Foong Chan; Jonathan J Deeks; Petra Macaskill; Les Irwig
Journal:  J Clin Epidemiol       Date:  2007-07-16       Impact factor: 6.437

3.  Development of two avidity-based assays to detect recent HIV type 1 seroconversion using a multisubtype gp41 recombinant protein.

Authors:  Xierong Wei; Xin Liu; Trudy Dobbs; Debra Kuehl; John N Nkengasong; Dale J Hu; Bharat S Parekh
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

4.  Making better decisions: construction of clinical scoring systems by the Spiegelhalter-Knill-Jones approach.

Authors:  D G Seymour; M Green; F G Vaz
Journal:  BMJ       Date:  1990-01-27

5.  Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors.

Authors:  Daisy M Machado; Eric L Delwart; Ricardo S Diaz; Carlos F de Oliveira; Katia Alves; Bhupat D Rawal; Marian Sullivan; Marta Gwinn; Kenneth A Clark; Michael P Busch
Journal:  AIDS       Date:  2002-01-04       Impact factor: 4.177

6.  Differences in the temporal trends of HIV seroincidence and seroprevalence among sexually transmitted disease clinic patients, 1989-1998: application of the serologic testing algorithm for recent HIV seroconversion.

Authors:  S Schwarcz; T Kellogg; W McFarland; B Louie; R Kohn; M Busch; M Katz; G Bolan; J Klausner; H Weinstock
Journal:  Am J Epidemiol       Date:  2001-05-15       Impact factor: 4.897

7.  Avidity Index for anti-HIV antibodies: comparison between third- and fourth-generation automated immunoassays.

Authors:  Barbara Suligoi; Anna Rodella; Mariangela Raimondo; Vincenza Regine; Luigina Terlenghi; Nino Manca; Salvatore Casari; Laura Camoni; Maria Cristina Salfa; Claudio Galli
Journal:  J Clin Microbiol       Date:  2011-05-04       Impact factor: 5.948

8.  Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies.

Authors:  Yen T Duong; Maofeng Qiu; Anindya K De; Keisha Jackson; Trudy Dobbs; Andrea A Kim; John N Nkengasong; Bharat S Parekh
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

9.  High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease.

Authors:  Jörg Schüpbach; Leslie R Bisset; Stephan Regenass; Philippe Bürgisser; Meri Gorgievski; Ingrid Steffen; Corinne Andreutti; Gladys Martinetti; Cyril Shah; Sabine Yerly; Thomas Klimkait; Martin Gebhardt; Franziska Schöni-Affolter; Martin Rickenbach; J Barth; M Battegay; E Bernascon; J Böni; H C Bucher; P Bürgisser; C Burton-Jeangros; A Calmy; M Cavassini; R Dubs; M Egger; L Elzi; J Fehr; M Fischer; M Flepp; P Francioli; H Furrer; C A Fux; M Gorgievski; H Günthard; B Hasse; H H Hirsch; B Hirschel; I Hösli; C Kahlert; L Kaiser; O Keiser; C Kind; T Klimkait; H Kovari; B Ledergerber; G Martinetti; B Martinez de Tejada; N Müller; D Nadal; G Pantaleo; A Rauch; S Regenass; M Rickenbach; C Rudin; P Schmid; D Schultze; F Schöni-Affolter; J Schüpbach; R Speck; P Taffé; A Telenti; A Trkola; P Vernazza; V von Wyl; R Weber; S Yerly
Journal:  BMC Infect Dis       Date:  2011-09-26       Impact factor: 3.090

10.  Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation.

Authors:  Jörg Schüpbach; Martin D Gebhardt; Zuzana Tomasik; Christoph Niederhauser; Sabine Yerly; Philippe Bürgisser; Lukas Matter; Meri Gorgievski; Rolf Dubs; Detlev Schultze; Ingrid Steffen; Corinne Andreutti; Gladys Martinetti; Bruno Güntert; Roger Staub; Synove Daneel; Pietro Vernazza
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069

View more
  5 in total

1.  How Can Progress Toward Ending the Human Immunodeficiency Virus Epidemic in the United States Be Monitored?

Authors:  Kate M Mitchell; Mathieu Maheu-Giroux; Dobromir Dimitrov; Mia Moore; James P Hughes; Deborah Donnell; Chris Beyrer; Wafaa M El-Sadr; Myron S Cohen; Marie Claude Boily
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

2.  Challenges to the performance of current HIV diagnostic assays and the need for centralized specimen archives: a review of the Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) repository.

Authors:  Shelley N Facente; Michael P Busch; Eduard Grebe; Christopher D Pilcher; Alex Welte; Brian Rice; Gary Murphy
Journal:  Gates Open Res       Date:  2019-07-23

3.  Estimated dates of detectable infection (EDDIs) as an improvement upon Fiebig staging for HIV infection dating.

Authors:  S N Facente; E Grebe; C D Pilcher; M P Busch; G Murphy; A Welte
Journal:  Epidemiol Infect       Date:  2020-02-19       Impact factor: 2.451

4.  Quantitative interpretation of Sedia LAg Assay test results after HIV diagnosis.

Authors:  Joseph B Sempa; Eduard Grebe; Alex Welte
Journal:  PLoS One       Date:  2022-07-28       Impact factor: 3.752

Review 5.  Use of HIV Recency Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review.

Authors:  Shelley N Facente; Eduard Grebe; Andrew D Maher; Douglas Fox; Susan Scheer; Mary Mahy; Shona Dalal; David Lowrance; Kimberly Marsh
Journal:  JMIR Public Health Surveill       Date:  2022-03-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.